IRIS Institutional Research Information System - OPENBS Open Archive UniBS

Cosentini, Deborah
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.179
AS - Asia 2.012
EU - Europa 1.763
SA - Sud America 387
AF - Africa 42
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.386
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.097
SG - Singapore 848
CN - Cina 488
IT - Italia 374
PL - Polonia 336
BR - Brasile 320
DE - Germania 235
HK - Hong Kong 230
FI - Finlandia 205
VN - Vietnam 126
UA - Ucraina 102
GB - Regno Unito 97
RU - Federazione Russa 85
TR - Turchia 84
IE - Irlanda 80
IN - India 55
CA - Canada 49
SE - Svezia 48
CZ - Repubblica Ceca 40
BD - Bangladesh 39
ID - Indonesia 39
FR - Francia 34
JP - Giappone 30
AR - Argentina 28
BE - Belgio 26
ES - Italia 25
MX - Messico 22
NL - Olanda 22
ZA - Sudafrica 19
AT - Austria 14
CH - Svizzera 11
EC - Ecuador 11
CL - Cile 9
PT - Portogallo 9
AE - Emirati Arabi Uniti 7
SA - Arabia Saudita 7
UZ - Uzbekistan 7
IQ - Iraq 6
LT - Lituania 6
MA - Marocco 6
PK - Pakistan 6
AZ - Azerbaigian 5
DZ - Algeria 5
CR - Costa Rica 4
EG - Egitto 4
JO - Giordania 4
LB - Libano 4
PY - Paraguay 4
TW - Taiwan 4
BG - Bulgaria 3
GY - Guiana 3
JM - Giamaica 3
KE - Kenya 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LV - Lettonia 3
PA - Panama 3
PE - Perù 3
VE - Venezuela 3
AL - Albania 2
CO - Colombia 2
EE - Estonia 2
NP - Nepal 2
OM - Oman 2
PH - Filippine 2
PS - Palestinian Territory 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
UY - Uruguay 2
ZW - Zimbabwe 2
AU - Australia 1
BH - Bahrain 1
BO - Bolivia 1
CY - Cipro 1
ET - Etiopia 1
EU - Europa 1
FK - Isole Falkland (Malvinas) 1
HN - Honduras 1
IL - Israele 1
IR - Iran 1
LA - Repubblica Popolare Democratica del Laos 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
QA - Qatar 1
SY - Repubblica araba siriana 1
TG - Togo 1
Totale 8.386
Salva come PNG Salva come JPEG
Città #
Ashburn 391
Dallas 374
Singapore 366
Warsaw 332
Fairfield 275
Chicago 234
Hong Kong 229
Los Angeles 184
Chandler 157
New York 154
Beijing 142
Helsinki 139
Seattle 124
Houston 113
Woodbridge 111
Salt Lake City 100
Wilmington 98
Munich 92
Cambridge 78
Jacksonville 77
Princeton 69
Istanbul 66
Secaucus 60
Buffalo 59
Brescia 53
Tampa 51
Turku 48
Dublin 46
Elk Grove Village 46
Ann Arbor 43
Boardman 43
Moscow 42
Redondo Beach 38
Shanghai 38
Jakarta 37
Milan 36
Dalmine 34
Brno 32
Ho Chi Minh City 30
The Dalles 30
West Jordan 30
Des Moines 28
Dong Ket 28
Sterling 27
Brussels 26
São Paulo 26
San Francisco 25
Hanoi 24
Santa Clara 24
Menlo Park 22
London 21
Dearborn 20
Lancaster 20
Romola 20
Orem 19
Naples 18
Nuremberg 18
Rio de Janeiro 18
Rome 18
Stockholm 18
Nanjing 17
Poplar 17
Brooklyn 16
Montreal 16
Johannesburg 15
Phoenix 15
Boston 14
Dulles 14
Lappeenranta 14
Mumbai 13
Pune 13
San Diego 13
Tokyo 13
Atlanta 12
Washington 12
Chennai 11
Denver 11
Frankfurt am Main 11
Detroit 10
Miami 10
Tianjin 10
Gumyojicho 9
Kansas City 9
Nanchang 9
Toronto 9
Turin 9
Ankara 8
Biên Hòa 8
Changsha 8
Council Bluffs 8
Düsseldorf 8
Guangzhou 8
Belo Horizonte 7
Brasília 7
Charlotte 7
Jinan 7
Lisbon 7
Manchester 7
New Delhi 7
Olomouc 7
Totale 5.547
Salva come PNG Salva come JPEG
Nome #
Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer 762
Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience. 359
Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma 231
Eight‐week interval in flushing and locking port‐a‐cath in cancer patients: A single‐institution experience and systematic review 229
In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures☆ 223
Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures 223
IN VITRO ANTITUMOR ACTIVITY OF PROGESTERONE IN HUMAN ADRENOCORTICAL CARCINOMA 204
Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells 195
Immunotherapy failure in adrenocortical cancer: where next? 194
Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma. 184
The guanine nucleotide exchange factor VAV2 as a new prognostic parameter in adrenocortical carcinoma 181
Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options 176
Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria 169
Antineoplastic Activity of Artemisinin in Adrenocortical Carcinoma 158
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients 155
Cost-effectiveness of model-based eligibility for lung cancer screening in the routine clinical practice 153
Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines? 151
Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report 143
Changes in eating habits and food preferences in breast cancer patients undergoing adjuvant chemotherapy 124
Efficacy of the DigniCap System in preventing chemotherapy-induced alopecia in breast cancer patients is not related to patient characteristics or side effects of the device 120
Treatment with 90Y/177Lu DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors 118
A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma 111
Transformation of prostate adenocarcinoma into small-cell neuroendocrine cancer under androgen deprivation therapy: Much is achieved but more information is needed 111
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study 109
Ribociclib Cytotoxicity Alone Or Combined With Progesterone And/Or Mitotane In In Vitro Adrenocortical Carcinoma Cells 107
Accurate Triage of Oncological Patients for Safely Continuing Cancer Therapy During the SARS-CoV-2 Pandemic 101
Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma 99
Assessment of DXA derived bone quality indexes and bone geometry parameters in early breast cancer patients: A single center cross-sectional study 98
Preclinical Evidence of Progesterone as a New Pharmacological Strategy in Human Adrenocortical Carcinoma Cell Lines 97
Ovarian Strumal Carcinoid: Case Report, Systematic Literature Review and Pooled Analysis 96
Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art? 94
The long and winding road to effective immunotherapy in patients with adrenocortical carcinoma 91
Microvascular Structural Alterations in Cancer Patients Treated With Antiangiogenic Drugs 91
Estrogen-Like Effect of Mitotane Explained by Its Agonist Activity on Estrogen Receptor-α 91
Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen 88
Trabectedin impairs invasiveness and metastasis in adrenocortical carcinoma preclinical models 87
Letter to the editor from Berruti et al: "Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival" 86
Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study 84
Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy 82
Correction to: A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma (Cells, (2022), 11, 9, (1439), 10.3390/cells11091439) 81
Outcome of brain metastases from adrenocortical carcinoma: a pooled analysis 80
Frequency and outcome of SARS-CoV-2 infection in patients with adrenocortical carcinoma followed at a reference center in Italy 80
Gastrointestinal Toxicity of Antibody Drug Conjugates (ADCs) in Metastatic Breast Cancer: A Pooled Analysis 79
Taste Alterations Do Not Affect Change in Food Habits and Body Weight in Breast Cancer Patients 79
Fat Body Mass and Vertebral Fracture Progression in Women With Breast Cancer 78
Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma 78
Is weight gain preventable in women with early breast cancer undergoing chemotherapy? A real-world study on dietary pattern, physical activity, and body weight before and after chemotherapy 78
Feasibility and Activity of Megestrol Acetate in Addition to Etoposide, Doxorubicin, Cisplatin, and Mitotane as First-Line Therapy in Patients with Metastatic/Unresectable Adrenocortical Carcinoma with Low Performance Status 76
Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question 75
Taste alterations during neo/adjuvant chemotherapy and subsequent follow-up in breast cancer patients: a prospective single-center clinical study 75
Changes in body composition in early breast cancer patients treated with aromatase inhibitors 75
Sleep disturbances and restless legs syndrome in postmenopausal women with early breast cancer given adjuvant aromatase inhibitor therapy 75
Correction: Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors 74
Body composition in early breast cancer patients treated with adjuvant aromatase inhibitors: Does dietary counseling matter? 73
Progression of vertebral fractures in patients with adrenocortical carcinoma undergoing mitotane therapy 73
Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors 71
Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies 68
Is it time to tailor treatments in androgen receptor positive salivary gland cancers? 66
Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma 65
Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies 64
Regorafenib-related erythrocytosis in metastatic extra-gastrointestinal stromal tumor: a case report 63
Role of Body Composition in the Prediction of Skeletal Fragility Induced by Hormone Deprivation Therapies in Cancer Patients 62
The Evolving Treatment Landscape of Medullary Thyroid Cancer 60
S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study 60
Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: Reliability of who fracture risk assessment tool (frax) and bone mineral density in real-life clinical practice 60
Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors 60
Adjuvant denosumab for early breast cancer-Evidence and controversy 58
Germline NGS targeted analysis in adult patients with sporadic adrenocortical carcinoma 52
The Value of Local Therapies in Advanced Adrenocortical Carcinoma 51
null 51
Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group 50
Real-world use of multigene signatures in early breast cancer: differences to clinical trials 48
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial 47
Molecular genotyping of adrenocortical carcinoma: A systematic analysis of published literature 2019-2021 46
Letter re: Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study 38
The role of 2-[18F]FDG PET/CT in adrenocortical carcinoma: a systematic review 2
Totale 8.546
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.348
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.348
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021415 0 0 0 0 0 74 32 68 48 88 38 67
2021/2022398 37 10 12 76 19 27 15 20 17 55 31 79
2022/2023440 50 22 27 31 36 96 4 48 56 16 29 25
2023/2024918 43 31 74 75 74 171 27 50 129 61 23 160
2024/20252.833 54 45 30 414 174 131 154 88 293 122 675 653
2025/20262.359 343 507 570 484 392 63 0 0 0 0 0 0
Totale 8.546